CN103282777A - 治疗癌症的方法 - Google Patents

治疗癌症的方法 Download PDF

Info

Publication number
CN103282777A
CN103282777A CN2011800634321A CN201180063432A CN103282777A CN 103282777 A CN103282777 A CN 103282777A CN 2011800634321 A CN2011800634321 A CN 2011800634321A CN 201180063432 A CN201180063432 A CN 201180063432A CN 103282777 A CN103282777 A CN 103282777A
Authority
CN
China
Prior art keywords
weeks
treatment
inhibition
additional chemical
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800634321A
Other languages
English (en)
Chinese (zh)
Inventor
J.A.雷迪
C.P.利蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CN103282777A publication Critical patent/CN103282777A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011800634321A 2010-11-12 2011-11-11 治疗癌症的方法 Pending CN103282777A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41327510P 2010-11-12 2010-11-12
US61/413,275 2010-11-12
PCT/US2011/060407 WO2012065085A1 (en) 2010-11-12 2011-11-11 Methods of treating cancer

Publications (1)

Publication Number Publication Date
CN103282777A true CN103282777A (zh) 2013-09-04

Family

ID=46048353

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800634321A Pending CN103282777A (zh) 2010-11-12 2011-11-11 治疗癌症的方法
CN201180061415.4A Expired - Fee Related CN103403552B (zh) 2010-11-12 2011-11-11 治疗癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180061415.4A Expired - Fee Related CN103403552B (zh) 2010-11-12 2011-11-11 治疗癌症的方法

Country Status (15)

Country Link
US (3) US8987281B2 (https=)
EP (2) EP2638397A4 (https=)
JP (2) JP2013542264A (https=)
KR (2) KR20130140033A (https=)
CN (2) CN103282777A (https=)
AU (2) AU2011325989C1 (https=)
BR (2) BR112013011659A2 (https=)
CA (2) CA2817219A1 (https=)
CL (2) CL2013001322A1 (https=)
EA (2) EA025069B1 (https=)
IL (2) IL226246A0 (https=)
MX (2) MX2013005194A (https=)
SG (2) SG190244A1 (https=)
WO (2) WO2012065085A1 (https=)
ZA (2) ZA201304225B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103816548A (zh) * 2014-03-11 2014-05-28 北京林业大学 靶向亲水性聚合物-雷公藤甲素结合物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
KR20130140033A (ko) 2010-11-12 2013-12-23 엔도사이트, 인코포레이티드 암을 치료하는 방법들
KR20140022879A (ko) * 2011-04-12 2014-02-25 엔도사이트, 인코포레이티드 고체 약학 조성물
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
WO2015077303A1 (en) 2013-11-19 2015-05-28 Purdue Research Foundation Patient selection method for inflammation
MX385194B (es) 2014-02-21 2025-03-14 Nektar Therapeutics India Pvt Ltd Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
EP3131587A4 (en) * 2014-04-14 2017-11-01 Endocyte, Inc. Drug delivery conjugates for treating resistant cancer and for use in combination therapy
CN112638363B (zh) 2018-08-31 2025-01-24 太阳医药工业有限公司 卡铂的肠胃外剂型

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203759A (zh) * 2005-03-30 2008-06-18 普渡研究基金会 使用细胞叶酸维生素受体定量法而用于癌症预后的方法
US20100004276A1 (en) * 2003-01-27 2010-01-07 Vlahov Iontcho R Vitamin receptor binding drug delivery conjugates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
WO2003097647A1 (en) * 2002-05-15 2003-11-27 Endocyte, Inc. Vitamin-mitomycin conjugates
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
CN100381177C (zh) * 2003-01-27 2008-04-16 恩多塞特公司 维生素受体结合递药缀合物
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
AU2009293140A1 (en) * 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
GB2463401B (en) * 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
EP2460013A4 (en) 2009-07-31 2013-04-03 Endocyte Inc ON FOLLOWING DIAGNOSIS AND TREATMENT
KR20130140033A (ko) 2010-11-12 2013-12-23 엔도사이트, 인코포레이티드 암을 치료하는 방법들

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100004276A1 (en) * 2003-01-27 2010-01-07 Vlahov Iontcho R Vitamin receptor binding drug delivery conjugates
CN101203759A (zh) * 2005-03-30 2008-06-18 普渡研究基金会 使用细胞叶酸维生素受体定量法而用于癌症预后的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103816548A (zh) * 2014-03-11 2014-05-28 北京林业大学 靶向亲水性聚合物-雷公藤甲素结合物

Also Published As

Publication number Publication date
EA025069B1 (ru) 2016-11-30
WO2012065079A4 (en) 2012-07-12
SG190244A1 (en) 2013-06-28
US8883737B2 (en) 2014-11-11
WO2012065085A4 (en) 2012-07-12
BR112013011590A2 (pt) 2019-09-24
WO2012065079A1 (en) 2012-05-18
IL226246A0 (en) 2013-07-31
HK1189272A1 (zh) 2014-05-30
EA201390695A1 (ru) 2013-12-30
US20140066383A1 (en) 2014-03-06
CN103403552A (zh) 2013-11-20
CA2817223A1 (en) 2012-05-18
BR112013011659A2 (pt) 2016-08-02
CL2013001322A1 (es) 2014-03-28
US20130330326A1 (en) 2013-12-12
AU2011325982B2 (en) 2014-10-09
MX2013005194A (es) 2013-06-28
AU2011325989C1 (en) 2015-04-23
AU2011325989A1 (en) 2013-04-11
AU2011325989B2 (en) 2014-10-09
JP2013542264A (ja) 2013-11-21
EP2638397A4 (en) 2016-06-01
EP2638395A4 (en) 2016-06-01
KR20130140033A (ko) 2013-12-23
KR20130140032A (ko) 2013-12-23
ZA201304226B (en) 2017-11-29
EA201390694A1 (ru) 2013-12-30
EP2638397A1 (en) 2013-09-18
SG190245A1 (en) 2013-06-28
JP2013542263A (ja) 2013-11-21
ZA201304225B (en) 2018-05-30
CL2013001324A1 (es) 2014-05-16
EA026168B1 (ru) 2017-03-31
CN103403552B (zh) 2016-01-06
MX2013005196A (es) 2013-06-28
US8987281B2 (en) 2015-03-24
WO2012065085A1 (en) 2012-05-18
IL226247A0 (en) 2013-06-27
EP2638395A1 (en) 2013-09-18
US20120122893A1 (en) 2012-05-17
AU2011325982C1 (en) 2015-08-20
CA2817219A1 (en) 2012-05-18
AU2011325982A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
AU2011325989B2 (en) Methods of treating cancer
Li et al. Autophagy inhibition recovers deficient ICD-based cancer immunotherapy
US20110052580A1 (en) Use of picoplatin and bevacizumab to treat colorectal cancer
CN110573166A (zh) 用于癌症治疗的吉西他滨衍生物
Parrasia et al. Targeting pancreatic ductal adenocarcinoma (PDAC)
WO2019113072A1 (en) Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer
US20130252904A1 (en) Compositions and methods for treating cancer
HK1189057A (en) Methods of treating cancer
HK1189272B (en) Methods of treating cancer
AU2013204338A1 (en) Methods of treating cancer
AU2013204342A1 (en) Methods of treating cancer
Jiang Nanoscale Coordination Polymers Deliver Chemotherapeutics and Innate Immune Modulators for Cancer Therapy
Brown et al. Recent Clinical Disclosures and SMR Award. Highlights from The Society for Medicines Research Symposium. London, UK-December 5, 2019
US20230092005A1 (en) Compositions and methods for treating cancer and tumor
WO2026039718A1 (en) Cancer treatment using 5,6-dihydro-4h-benzo[de] quinoline-camptothecin
Gajdosik Depatuxizumab mafodotin. Anti-egfr antibody-drug conjugate, treatment of glioblastoma multiforme

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1189057

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130904

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1189057

Country of ref document: HK